Cargando…

Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function

AIMS : The increasing prevalence of ischaemic stroke (IS) can partly be explained by the likewise growing number of patients with chronic kidney disease (CKD). Risk scores have been developed to identify high-risk patients, allowing for personalized anticoagulation therapy. However, predictive perfo...

Descripción completa

Detalles Bibliográficos
Autores principales: de Jong, Ype, Fu, Edouard L, van Diepen, Merel, Trevisan, Marco, Szummer, Karolina, Dekker, Friedo W, Carrero, Juan J, Ocak, Gurbey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046502/
https://www.ncbi.nlm.nih.gov/pubmed/33769473
http://dx.doi.org/10.1093/eurheartj/ehab059
_version_ 1783678864369647616
author de Jong, Ype
Fu, Edouard L
van Diepen, Merel
Trevisan, Marco
Szummer, Karolina
Dekker, Friedo W
Carrero, Juan J
Ocak, Gurbey
author_facet de Jong, Ype
Fu, Edouard L
van Diepen, Merel
Trevisan, Marco
Szummer, Karolina
Dekker, Friedo W
Carrero, Juan J
Ocak, Gurbey
author_sort de Jong, Ype
collection PubMed
description AIMS : The increasing prevalence of ischaemic stroke (IS) can partly be explained by the likewise growing number of patients with chronic kidney disease (CKD). Risk scores have been developed to identify high-risk patients, allowing for personalized anticoagulation therapy. However, predictive performance in CKD is unclear. The aim of this study is to validate six commonly used risk scores for IS in atrial fibrillation (AF) patients across the spectrum of kidney function. METHODS AND RESULTS : Overall, 36 004 subjects with newly diagnosed AF from SCREAM (Stockholm CREAtinine Measurements), a healthcare utilization cohort of Stockholm residents, were included. Predictive performance of the AFI, CHADS(2), Modified CHADS(2), CHA(2)DS(2)-VASc, ATRIA, and GARFIELD-AF risk scores was evaluated across three strata of kidney function: normal kidney function [estimated glomerular filtration rate (eGFR) >60 mL/min/1.73 m(2)], mild CKD (eGFR 30–60 mL/min/1.73 m(2)), and advanced CKD (eGFR <30 mL/min/1.73 m(2)). Predictive performance was assessed by discrimination and calibration. During 1.9 years, 3069 (8.5%) patients suffered an IS. Discrimination was dependent on eGFR: the median c-statistic in normal eGFR was 0.75 (range 0.68–0.78), but decreased to 0.68 (0.58–0.73) and 0.68 (0.55–0.74) for mild and advanced CKD, respectively. Calibration was reasonable and largely independent of eGFR. The Modified CHADS(2) score showed good performance across kidney function strata, both for discrimination [c-statistic: 0.78 (95% confidence interval 0.77–0.79), 0.73 (0.71–0.74) and 0.74 (0.69–0.79), respectively] and calibration. CONCLUSION : In the most clinically relevant stages of CKD, predictive performance of the majority of risk scores was poor, increasing the risk of misclassification and thus of over- or undertreatment. The Modified CHADS(2) score performed good and consistently across all kidney function strata, and should therefore be preferred for risk estimation in AF patients.
format Online
Article
Text
id pubmed-8046502
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-80465022021-04-21 Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function de Jong, Ype Fu, Edouard L van Diepen, Merel Trevisan, Marco Szummer, Karolina Dekker, Friedo W Carrero, Juan J Ocak, Gurbey Eur Heart J Clinical Research AIMS : The increasing prevalence of ischaemic stroke (IS) can partly be explained by the likewise growing number of patients with chronic kidney disease (CKD). Risk scores have been developed to identify high-risk patients, allowing for personalized anticoagulation therapy. However, predictive performance in CKD is unclear. The aim of this study is to validate six commonly used risk scores for IS in atrial fibrillation (AF) patients across the spectrum of kidney function. METHODS AND RESULTS : Overall, 36 004 subjects with newly diagnosed AF from SCREAM (Stockholm CREAtinine Measurements), a healthcare utilization cohort of Stockholm residents, were included. Predictive performance of the AFI, CHADS(2), Modified CHADS(2), CHA(2)DS(2)-VASc, ATRIA, and GARFIELD-AF risk scores was evaluated across three strata of kidney function: normal kidney function [estimated glomerular filtration rate (eGFR) >60 mL/min/1.73 m(2)], mild CKD (eGFR 30–60 mL/min/1.73 m(2)), and advanced CKD (eGFR <30 mL/min/1.73 m(2)). Predictive performance was assessed by discrimination and calibration. During 1.9 years, 3069 (8.5%) patients suffered an IS. Discrimination was dependent on eGFR: the median c-statistic in normal eGFR was 0.75 (range 0.68–0.78), but decreased to 0.68 (0.58–0.73) and 0.68 (0.55–0.74) for mild and advanced CKD, respectively. Calibration was reasonable and largely independent of eGFR. The Modified CHADS(2) score showed good performance across kidney function strata, both for discrimination [c-statistic: 0.78 (95% confidence interval 0.77–0.79), 0.73 (0.71–0.74) and 0.74 (0.69–0.79), respectively] and calibration. CONCLUSION : In the most clinically relevant stages of CKD, predictive performance of the majority of risk scores was poor, increasing the risk of misclassification and thus of over- or undertreatment. The Modified CHADS(2) score performed good and consistently across all kidney function strata, and should therefore be preferred for risk estimation in AF patients. Oxford University Press 2021-03-26 /pmc/articles/PMC8046502/ /pubmed/33769473 http://dx.doi.org/10.1093/eurheartj/ehab059 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Clinical Research
de Jong, Ype
Fu, Edouard L
van Diepen, Merel
Trevisan, Marco
Szummer, Karolina
Dekker, Friedo W
Carrero, Juan J
Ocak, Gurbey
Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function
title Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function
title_full Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function
title_fullStr Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function
title_full_unstemmed Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function
title_short Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function
title_sort validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046502/
https://www.ncbi.nlm.nih.gov/pubmed/33769473
http://dx.doi.org/10.1093/eurheartj/ehab059
work_keys_str_mv AT dejongype validationofriskscoresforischaemicstrokeinatrialfibrillationacrossthespectrumofkidneyfunction
AT fuedouardl validationofriskscoresforischaemicstrokeinatrialfibrillationacrossthespectrumofkidneyfunction
AT vandiepenmerel validationofriskscoresforischaemicstrokeinatrialfibrillationacrossthespectrumofkidneyfunction
AT trevisanmarco validationofriskscoresforischaemicstrokeinatrialfibrillationacrossthespectrumofkidneyfunction
AT szummerkarolina validationofriskscoresforischaemicstrokeinatrialfibrillationacrossthespectrumofkidneyfunction
AT dekkerfriedow validationofriskscoresforischaemicstrokeinatrialfibrillationacrossthespectrumofkidneyfunction
AT carrerojuanj validationofriskscoresforischaemicstrokeinatrialfibrillationacrossthespectrumofkidneyfunction
AT ocakgurbey validationofriskscoresforischaemicstrokeinatrialfibrillationacrossthespectrumofkidneyfunction